Motilal Oswal Initiates Buy Coverage on Molbio Diagnostics with 19-21% Upside
Motilal Oswal Financial Services has initiated coverage on Molbio Diagnostics with a Buy rating and target price implying 19-21% upside. The brokerage highlights Molbio's Truenat platform, a portable molecular testing system deployed in over 90 countries with 12,500 devices and 43 assays, as central to its growth. Emphasizing recurring revenue from test kits, Motilal Oswal expects strong earnings growth driven by assay expansion, international adoption, and diversification beyond tuberculosis. Projected revenue and profit growth over FY26-29 are supported by operating leverage, despite risks from government order dependence and working capital.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (73/100). Lens Score 44/100.
Outlets measured: thefinancialexpress, thefinancialexpress. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (72–78/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thefinancialexpress broke this story on 5 Oct, 09:00 am. Other outlets followed.